A virtual, decentralised observational follow-up study investigating feeding patterns in infancy and the associated parent-reported allergic manifestations, allergies and infections in childhood.

A virtual, decentralised observational follow-up study investigating feeding patterns in infancy and the associated parent-reported allergic manifestations, allergies and infections in childhood. - TEMPO Follow-Up

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON53433

Enrollment

Registered

2022-10-19

Start date

2022-09-30

Completion date

Unknown

Last updated

2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergies infections

Interventions

None listed

Eligibility

Age

2 Years to 11 Years

Inclusion criteria

Inclusion criteria: - Subject completed the final (12 months) visit in the TEMPO study. - Parents agree that their contact details will be shared with a third party for study purposes. - Parents agree that data collected in the TEMPO study will be used in the TEMPO Follow-Up study. - Parents provide written informed consent for participation in the TEMPO Follow-Up in accordance with local law.

Exclusion criteria

Exclusion criteria: - Parents who do not have a smartphone, tablet or personal computer with internet access.

Design outcomes

Primary

Measure	Time frame
1. The occurrence of • parent-reported allergic manifestations (e.g. symptoms suggestive of wheeze/asthma, eczema/atopic dermatitis, allergic rhinitis/hayfever, food allergy, pet allergy, house dust mite allergy). • parent-reported doctors diagnosis of asthma, allergic rhinitis/hayfever, eczema/atopic dermatitis, food allergy, pet allergy, house dust mite allergy. • parent-reported manifestations of infections (e.g. symptoms suggestive of respiratory tract, stomach, intestines, skin and urinary infections). • parent-reported doctors diagnosis of respiratory tract, stomach, intestines, skin and urinary infections. 2. The use of medications and/or a medical device (inhaler) to prevent or relieve allergic manifestations, allergies and/or infections. 3. Number of days hospitalised for allergic manifestations, allergies, and/or infections. 4. Number of visits to the emergency room for allergic manifestations, allergies, and/or infections.	—

Measure

Time frame

1. The occurrence of • parent-reported allergic manifestations (e.g. symptoms suggestive of wheeze/asthma, eczema/atopic dermatitis, allergic rhinitis/hayfever, food allergy, pet allergy, house dust mite allergy). • parent-reported doctor*s diagnosis of asthma, allergic rhinitis/hayfever, eczema/atopic dermatitis, food allergy, pet allergy, house dust mite allergy. • parent-reported manifestations of infections (e.g. symptoms suggestive of respiratory tract, stomach, intestines, skin and urinary infections). • parent-reported doctor*s diagnosis of respiratory tract, stomach, intestines, skin and urinary infections. 2. The use of medications and/or a medical device (inhaler) to prevent or relieve allergic manifestations, allergies and/or infections. 3. Number of days hospitalised for allergic manifestations, allergies, and/or infections. 4. Number of visits to the emergency room for allergic manifestations, allergies, and/or infections.

—

Countries

Netherlands

Outcome results